Haleon Slips as Growth Worries Build Ahead of Q3 Update

Haleon is investing £175m in a new oral health manufacturing facility in Madhya Pradesh, India, aiming to expand production capacity and reach more consumers, including rural populations with limited access to dental care. The company seeks to leverage local talent and infrastructure while addressing specific healthcare challenges and distribution hurdles in the region.

Haleon, a consumer health company, is investing £175m (US$235m) to build its first manufacturing site in Madhya Pradesh, India, aiming to reach one billion more consumers by 2030. The plant, set to open in January 2028, will create 500 permanent jobs and boost India's local economy. Haleon is also focusing on simplifying its supply chain and implementing automation, having installed 2,500 robotic equipment in 20 months.

Jefferies raised its price target for Haleon to 410p from 400p, citing a 70 basis point margin beat in H1. Haleon reported 3.1% organic sales growth in Q2, with Oral Health and Pain Relief segments performing well. Shares rose 0.28% to 364.10p. Jefferies expects 5%+ growth in H2 to meet guidance.

Haleon's H1 2026 operating margin expanded 160 bps to 24.3%, driven by cost savings, but organic sales growth was 2.6%. Jefferies notes strong execution but questions growth investment. Q2 sales grew 3.1%, with varied performance across segments. Jefferies raised its price target to 410 pence, citing 13% upside.

Haleon (HLN) announced a $2.0B cash tender offer for its 3.375% Fixed Rate Senior Notes due March 2027. The offer targets $1.999B in outstanding notes, with details available via the London Stock Exchange and the UK Financial Conduct Authority.

Haleon plc (HLN) completed a tender offer for $1.999B of its 2027 notes, accepting $1.34B. The offer, priced at $996.23 per $1,000, is part of its debt optimization strategy. Settlement is set for August 21, 2026, contingent on issuing new notes. HLN stock closed at $9.72, up 1.46%.